Tokujiro Yano
Overview
Explore the profile of Tokujiro Yano including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
88
Citations
911
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Akamine T, Takenaka T, Yano T, Okamoto T, Yamazaki K, Hamatake M, et al.
Eur J Surg Oncol
. 2024 Aug;
50(9):108374.
PMID: 39178719
Introduction: High recurrence rate following curative surgery for non-small cell lung cancer (NSCLC) presents a major clinical challenge. Understanding the site and timing of recurrence and their impact on post-recurrence...
2.
Okamoto T, Takenaka T, Yamazaki K, Hamatake M, Miura N, Takenoyama M, et al.
Anticancer Res
. 2023 Jul;
43(8):3543-3551.
PMID: 37500139
Background/aim: Adjuvant therapy using third-generation tyrosine kinase inhibitors (TKI) demonstrated improved central nervous system (CNS) disease-free survival after surgery in patients with epidermal growth factor receptor (EGFR) mutation-positive lung cancer....
3.
Yoshida D, Sugiyama M, Nakazono K, Oyama T, Hasegawa T, Kai S, et al.
Anticancer Res
. 2023 Jun;
43(7):3225-3233.
PMID: 37351999
Background/aim: This study aimed to evaluate the clinical impact of the level of inferior mesenteric artery (IMA) ligation in patients with advanced low rectal cancer. Patients And Methods: All enrolled...
4.
Takenaka T, Yano T, Yamazaki K, Okamoto T, Hamatake M, Takamori S, et al.
Thorac Cancer
. 2023 May;
14(18):1660-1667.
PMID: 37143400
Background: Long-term survival can be achieved with radical local therapy in some cases of postoperative recurrence of non-small cell lung cancer (NSCLC). Here, we evaluated post-recurrence survival (PRS) after treatment...
5.
Takenaka T, Yano T, Yamazaki K, Okamoto T, Hamatake M, Shimokawa M, et al.
JTCVS Open
. 2022 Aug;
10:370-381.
PMID: 36004269
Objectives: The optimal treatment for recurrent non-small cell lung cancer (NSCLC) has not been standardized. In this prospective cohort study, we evaluated post-recurrence survival (PRS) after treatment of recurrent NSCLC...
6.
Yano T, Hamatake M, Tokunaga S, Okamoto T, Yamazaki K, Miura T, et al.
Int J Clin Oncol
. 2022 Feb;
27(5):882-888.
PMID: 35212829
Background: To examine the effects of postoperative adjuvant chemotherapy for elderly (≥ 75 years of age) patients with completely resected non-small cell lung cancer (NSCLC), we conducted a multi-institutional and...
7.
Ikebe M, Kubo N, Fukuyama S, Yano T
BMJ Case Rep
. 2020 Jul;
13(7).
PMID: 32675117
A man in his 70s had undergone total gastrectomy for oesophagogastric junction cancer. Three years and 11 months later, he began to vomit after meals and was diagnosed with mediastinal...
8.
Kubo N, Kawanaka H, Hiroshige S, Tajiri H, Egashira A, Takeuchi H, et al.
Ann Gastroenterol Surg
. 2019 Dec;
3(6):630-637.
PMID: 31788651
Aim: Sarcopenia has been reported as a prognostic predictor in various conditions; however, it has not been examined in patients with perforation panperitonitis. Methods: A total of 103 consecutive patients...
9.
Okamoto T, Yano T, Shimokawa M, Takeo S, Yamazaki K, Sugio K, et al.
Lung Cancer
. 2018 Oct;
124:255-259.
PMID: 30268470
Objectives: Platinum-based combination chemotherapy is the standard postoperative adjuvant treatment for pathological stage II/III non-small cell lung cancer (NSCLC). Oral S-1 therapy has good efficacy and relatively low toxicity for...
10.
Yano T, Kawashima O, Takeo S, Adachi H, Tagawa T, Fukuyama S, et al.
Semin Thorac Cardiovasc Surg
. 2018 Apr;
29(4):540-547.
PMID: 29698655
The operative morbidity rate in elderly patients with lung cancer is high in comparison to nonelderly patients, probably because of the increase in comorbidities that occurs with aging. However, previous...